Navigation Links
AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing

CINCINNATI, Feb. 14, 2011 /PRNewswire/ -- AssureRx Health, Inc. today announced that it has expanded its laboratory-developed GeneSightRx® pharmacogenetic test with a sixth gene, CYP2C9, to further support clinicians in prescribing medications for behavioral health patients.

The addition of the CYP2C9 gene, variations of which can cause loss of function involved in the metabolism of certain psychotropic medications, provides physicians with further information on gene polymorphisms responsible for variations in the metabolism of antidepressant and antipsychotic medications. GeneSightRx will now measure and analyze fifty clinically important genetic variants of six genes that affect patients' response to medications prescribed in psychiatric medicine.

The enhanced six-gene Web-based therapeutic decision support product analyzes genetic variants which may affect a patient's ability to tolerate or respond to psychotropic medications. GeneSightRx integrates the analysis of genes and their variations to obtain an evidence-based pharmacogenetic profile. These gene variations are then analyzed against 26 FDA-approved drugs to help physicians select the appropriate psychotropic medications for each patient. In addition to the CYP2C9 gene, GeneSightRx analyzes genetic variations in the CYP2D6, CYP2C19, and CYP1A2 genes, as well as the serotonin transporter gene SLC6A4 and the serotonin 2A receptor gene 5HTR2A.  

"GeneSightRx provides objective measures to help physicians avoid prescribing drugs that may cause adverse drug reactions or poor response in certain patients. Improving drug safety is a key company objective," said James S. Burns, president & CEO of AssureRx. "Our goal is to build the leading medical informatics company providing pharmacogenetic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders."

John A. Bellano, senior vice president of sales & commercial programs at AssureRx Health said, "Variations of the CYP2C9 gene affect several commonly used psychiatric medications. Its inclusion in GeneSightRx allows us to further differentiate the AssureRx technology from routine genotyping tests. Enhancing GeneSightRx with the CYP2C9 gene now provides physicians with even more information about their patients' unique genetic fingerprint, allowing them to make more informed medication choices for each individual patient. Our goal is to provide treatment-oriented support that helps reduce the risk of side effects and delays in achieving response."

About GeneSightRxGeneSightRx is a laboratory developed genetic test that uses cutting edge technology to measure and analyze clinically important genetic variants in psychiatric medicine. The results of the report can help a doctor understand the way a patient's unique genetic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, the FDA approved manufacturer's drug label, and scientifically valid published reports and/or proven pharmacology. Quick turnaround time, combined with a customized report of the patient's genetic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenetics and GeneSightRx, please click here. Be sure to watch the educational video.

About AssureRx HealthCincinnati-based AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenetics and is dedicated to helping physicians determine the right drug at the right dose for individual patients suffering from psychiatric disorders. The company was founded in 2006 to commercialize industry-leading personalized medicine technology. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators.Contacts:John A. BellanoSenior Vice President, Sales & Commercial ProgramsAssureRx Health Inc.Tel: (513) 234-0510e-mail: jbellano@assurerxhealth.comAndreas Marathovouniotis or David Schull Russo PartnersTel: (212) 845-4235 or (212) 845-4271e-mail: or

SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
2. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
3. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
4. Cellectar Expands Clinical Management Team
5. VIA Pharmaceuticals Expands Clinical Trial Program for VIA-2291 in Acute Coronary Syndrome
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. PAREXEL Expands Global Clinical Pharmacology Capabilities
9. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
10. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... Research and Markets has announced the addition of ... report to their offering. ... The World Market for Companion Diagnostics covers the world market ... the report includes the following: , World ... Region (N. America, EU, ROW), 2015-2020 , World IVD ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
Breaking Medicine News(10 mins):